Cooking fish and drinking milk? Patterns in pottery use in the southeastern Baltic, 3300–2400 cal BC

yesA study of pottery vessel contents and use was undertaken in order to obtain information on food processed in Subneolithic and Neolithic vessels from Nida and Šventoji (3300–2400 cal BC). The aim is to assess pottery use during major changes in the coastal environment and in material culture. Bulk carbon and nitrogen isotope, lipid biomarker and compound specific carbon isotope analysis was undertaken on ‘foodcrusts’, charred deposits adhering to vessel surfaces, and absorbed residues from different vessel types. In addition, three archaeological seal bones were analysed for bulk collagen and compound specific carbon isotope analysis to establish collagen-lipid offsets to inform interpretation of the data. The results show that the majority of the vessels were used for processing aquatic products. At Nida the data suggest exploitation of freshwater resources and, in the later stages of occupation, dairying. Analysis of a small number of Subneolithic vessels from Šventoji produced results that are also consistent with processing of aquatic products. Other substances identified include Pinaceae sp. resin or tar and beeswax. These data demonstrate that identifying patterns in pottery use contributes to understanding Neolithisation processes

Where Brain, Body and World Collide

The production cross section of electrons from semileptonic decays of beauty hadrons was measured at mid-rapidity (|y| < 0.8) in the transverse momentum range 1 < pt < 8 Gev/c with the ALICE experiment at the CERN LHC in pp collisions at a center of mass energy sqrt{s} = 7 TeV using an integrated luminosity of 2.2 nb^{-1}. Electrons from beauty hadron decays were selected based on the displacement of the decay vertex from the collision vertex. A perturbative QCD calculation agrees with the measurement within uncertainties. The data were extrapolated to the full phase space to determine the total cross section for the production of beauty quark-antiquark pairs

Measurement of the Cross Section for Electromagnetic Dissociation with Neutron Emission in Pb-Pb Collisions at {\surd}sNN = 2.76 TeV

see paper for full list of authorsThe first measurement of neutron emission in electromagnetic dissociation of 208Pb nuclei at the LHC is presented. The measurement is performed using the neutron Zero Degree Calorimeters of the ALICE experiment, which detect neutral particles close to beam rapidity. The measured cross sections of single and mutual electromagnetic dissociation of Pb nuclei at {\surd}sNN = 2.76 TeV with neutron emission are {\sigma}_single EMD = 187.2{\pm}0.2 (stat.) +13.8-12.0 (syst.) b and {\sigma}_mutual EMD = 6.2 {\pm} 0.1 (stat.) {\pm}0.4 (syst.) b respectively. The experimental results are compared to the predictions from a relativistic electromagnetic dissociation model

Underlying Event measurements in pp collisions at sqrt(s) = 0.9 and 7 TeV with the ALICE experiment at the LHC

See paper for full list of authors - 37 pages, 65 figures, submitted to JHEPWe present measurements of Underlying Event observables in pp collisions at sqrt(s) = 0.9 and 7 TeV. The analysis is performed as a function of the highest charged-particle transverse momentum pT,LT in the event. Different regions are defined with respect to the azimuthal direction of the leading (highest transverse momentum) track: Toward, Transverse and Away. The Toward and Away regions collect the fragmentation products of the hardest partonic interaction. The Transverse region is expected to be most sensitive to the Underlying Event activity. The study is performed with charged particles above three different pT thresholds: 0.15, 0.5 and 1.0 GeV/c. In the Transverse region we observe an increase in the multiplicity of a factor 2-3 between the lower and higher collision energies, depending on the track pT threshold considered. Data are compared to Pythia 6.4, Pythia 8.1 and Phojet. On average, all models considered underestimate the multiplicity and summed pT in the Transverse region by about 10-30%

Suppression of high transverse momentum D mesons in central Pb--Pb collisions at sNN=2.76\sqrt{s_{NN}}=2.76 TeV

see paper for full list of authorsThe production of the prompt charm mesons $D^0$, $D^+$, $D^{*+}$, and their antiparticles, was measured with the ALICE detector in Pb-Pb collisions at the LHC, at a centre-of-mass energy $\sqrt{s_{NN}}=2.76$ TeV per nucleon--nucleon collision. The \pt-differential production yields in the range $

Measurement of electrons from beauty hadron decays in pp collisions at sqrt{s} = 7 TeV

See paper for full list of authorsThe production cross section of electrons from semileptonic decays of beauty hadrons was measured at mid-rapidity (|y| < 0.8) in the transverse momentum range 1 < pt < 8 Gev/c with the ALICE experiment at the CERN LHC in pp collisions at a center of mass energy sqrt{s} = 7 TeV using an integrated luminosity of 2.2 nb^{-1}. Electrons from beauty hadron decays were selected based on the displacement of the decay vertex from the collision vertex. A perturbative QCD calculation agrees with the measurement within uncertainties. The data were extrapolated to the full phase space to determine the total cross section for the production of beauty quark-antiquark pairs

D_s meson production at central rapidity in proton--proton collisions at sqrt(s) = 7 TeV

See paper for full list of authorsThe pt-differential inclusive production cross section of the prompt charm-strange meson D_s in the rapidity range |y| phi pi, with phi -> KK, and its charge conjugate, about 480 D_s mesons were counted, after selection cuts, in the transverse momentum range

Light vector meson production in pp collisions at sqrt(s) = 7 TeV

see paper for full list authorsThe ALICE experiment has measured low-mass dimuon production in pp collisions at \sqrt{s} = 7 TeV in the dimuon rapidity region 2.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA) : Rationale, Design, and Baseline Data

Altres ajuts: F. Hoffmann-La Roche Ltd.Background: Currently available treatments for Parkinson's disease (PD) do not slow clinical progression nor target alpha-synuclein, a key protein associated with the disease. Objective: The study objective was to evaluate the efficacy and safety of prasinezumab, a humanized monoclonal antibody that binds aggregated alpha-synuclein, in individuals with early PD. Methods: The PASADENA study is a multicenter, randomized, double-blind, placebo-controlled treatment study. Individuals with early PD, recruited across the US and Europe, received monthly intravenous doses of prasinezumab (1,500 or 4,500 mg) or placebo for a 52-week period (Part 1), followed by a 52-week extension (Part 2) in which all participants received active treatment. Key inclusion criteria were: aged 40-80 years; Hoehn & Yahr (H&Y) Stage I or II; time from diagnosis ≤2 years; having bradykinesia plus one other cardinal sign of PD (e.g., resting tremor, rigidity); DAT-SPECT imaging consistent with PD; and either treatment naïve or on a stable monoamine oxidase B (MAO-B) inhibitor dose. Study design assumptions for sample size and study duration were built using a patient cohort from the Parkinson's Progression Marker Initiative (PPMI). In this report, baseline characteristics are compared between the treatment-naïve and MAO-B inhibitor-treated PASADENA cohorts and between the PASADENA and PPMI populations. Results: Of the 443 patients screened, 316 were enrolled into the PASADENA study between June 2017 and November 2018, with an average age of 59.9 years and 67.4% being male. Mean time from diagnosis at baseline was 10.11 months, with 75.3% in H&Y Stage II. Baseline motor and non-motor symptoms (assessed using Movement Disorder Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS]) were similar in severity between the MAO-B inhibitor-treated and treatment-naïve PASADENA cohorts (MDS-UPDRS sum of Parts I + II + III [standard deviation (SD)]; 30.21 [11.96], 32.10 [13.20], respectively). The overall PASADENA population (63.6% treatment naïve and 36.4% on MAO-B inhibitor) showed a similar severity in MDS-UPDRS scores (e.g., MDS-UPDRS sum of Parts I + II + III [SD]; 31.41 [12.78], 32.63 [13.04], respectively) to the PPMI cohort (all treatment naïve). Conclusions: The PASADENA study population is suitable to investigate the potential of prasinezumab to slow disease progression in individuals with early PD. Trial Registration: NCT03100149